Xpert Bladder Cancer Detection

Xpert® Bladder Cancer Detection

Qualitative testing to detect the presence of genetic markers associated with bladder cancer in patients with haematuria

Ordering Info
  • Some early cancers may have signs and symptoms that can be noticed, bladder cancer is one of them.
    Catching bladder cancer early

    • allows for more treatment options
    • improves patients’ chances that it can be treated successfully1
    • saves overall healthcare costs2

    click here for more information

    Haematuria, or blood in the urine, is the most common symptom of bladder cancer.3 4 out of 5 people with bladder cancer have some blood in their urine4, however:

    • 80–90% patients with gross haematuria do NOT have cancer3
    • And over 95% of patients with microhaematuria do NOT have cancer5

    There are many common causes of haematuria; including urinary tract infection, nephrolithiasis (stones), polycystic kidney disease, trauma, benign prostatic hyperplasia (BPH) in older men, or, in some cases, even vigorous exercise.

    The proportion of patients presenting with haematuria whom actually do have bladder cancer is very small.

    Therefore it can be difficult for doctors to decide who may have cancer and who might have a different condition.

    In US clinical practice, only 13%-30% of all patients with hematuria are sent to the urologists for cystoscopy; because of this, it is estimated that there are over 20,000 missed cancer cases annually in the US.6

    It is extremely important to identify cancer patients early for the reasons identified above.

    There are many common causes of haematuria. Not knowing what is causing the haematuria leads to patient anxiety and uncertainty about the best way to follow up on the patient.

    A fast, non-invasive diagnostic test provides information to help to decide on the best follow-up strategy for the patient.

    Xpert Bladder Cancer Detection

    • A non-invasive biomarker test with proven clinical sensitivity and specificity for low and high-grade bladder cancer.
    • It utilizes the Cepheid GeneXpert Instrument Systems to measure the expression of five mRNA targets in 4.5ml urine sample in a self-contained cartridge.
    • This easy to use and fast solution requires less than two minutes of hands-on time with a total turnaround time of approximately 90 minutes, providing actionable results in real-time.
    • It offers an additional test which could help to determine if your patient presenting with haematuria does or does not have bladder cancer.
    • The test can easily be performed by technical staff or nurses, therefore freeing up the precious and costly time of the doctor.

    (1) www.cancer.org/content/dam/CRC/PDF/Public/8559.00.pdf; (2) WHO - Guide to cancer early diagnosis. ISBN 978-92-4-151194-0; (3) Yafi et al. Can Urol Assoc J. 2011 Apr;5(2):97-101; (4) Leal et al. Eur Urol. 2016 Mar;69(3): 438-472. (5) Messing et al. Cancer. 2006 Nov 1;107(9):2173-9. (6) David et al. Urology. 2017 Feb;100:20-26.

    • Cepheid - Our Vision for a Better Way
    • Catalog #: GXBLAD-CD-CE-10

      Xpert Bladder Cancer Detection
      Number of Tests: 10

    • How can I place an order?

      Submit your request using our Request Information form, or call 1.888.838.3222, select option 1.